The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Glenmark is the first company in India to market the innovative FDC of Indacaterol
A total of five observations for Goa and 17 for Monroe
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Subscribe To Our Newsletter & Stay Updated
